EBR Systems (ASX:EBR) enrolled and treated the first two patients in the company's WiSE System Utilization & Performance (WiSE-UP) study, according to a Thursday filing with the Australian bourse.
The study will evaluate real-world outcomes for heart failure patients receiving the company's WiSE left ventricular endocardial pacing system for cardiac resynchronization therapy, the filing said.
Shares of the company fell 2% in recent Thursday trade.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.